Positron emission tomography and drug discovery: Contributions to the understanding of pharmacokinetics, mechanism of action and disease state characterization

Molecular Imaging and Biology

Volumn 4, Issue 5, 2002, Pages 311-337

  Klimas, Michael T ^a  

^a GE HEALTHCARE   (United States)

Author keywords

Diagnosis; Disease characterization; Disease markers; Longitudinal evaluation; PET; Pharmacokinetics; Receptor occupancy

Indexed keywords

7 CHLORO 4 HYDROXY 3 [3 (4 METHOXYBENZYL)PHENYL] 2 QUINOLONE; [4((1 OXOPROPYL) PHENYLAMINO) 1 (2 PHENYLETHYL) 4 PIPERIDINECARBOXYLIC ACID METHYL ESTER]; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BEMESETRON; CARAZOLOL; CLOZAPINE; COCAINE; ESTER DERIVATIVE; FLEROXACIN; FLUOROURACIL; FLUOXETINE; KETAMINE; METHOTREXATE; N (2 DIMETHYLAMINOETHYL) 4 ACRIDINECARBOXAMIDE; NEUROLEPTIC AGENT; PINDOLOL; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RACLOPRIDE; RADIOLIGAND; RISPERIDONE; SDZMAR 327; SR 144385; SR 147963; SUMATRIPTAN; TETRAZINE DERIVATIVE; TRIAMCINOLONE ACETONIDE; TROVAFLOXICIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERAPAMIL;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CYCLOTRON; DISEASE COURSE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG INFORMATION; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; HEART MUSCLE ISCHEMIA; HUMAN; IN VIVO STUDY; LONGITUDINAL STUDY; MOLECULAR GENETICS; MOTOR DYSFUNCTION; NON INVASIVE MEASUREMENT; PHARMACODYNAMICS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REVIEW; VALIDATION PROCESS;

EID: 0036765028     PISSN: 15361632     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1536-1632(02)00017-3     Document Type: Review

References (225)

1. Burns, H.D.; Hamill, T.G.; Eng, W.S.; Francis B., Fioravanti,C.; Gibson, R.E. Positron emission tomography neuroreceptor imaging as a tool in drug discovery, research and development. Curr. Opin. Chem. Biol. 3:388-394; 1999.
2. Hietala, J. Ligand-receptor interactions as studied by PET: implications for drug development. Ann. Med. 31:438-443; 1999.
3. Fischman, A.J.; Alpert, N.M.; Babich, J.W.; Rubin R.H. The role of positron emission tomography in pharmacokinetic analysis. Drug Metab. Rev. 29:923-956; 1997.
4. Yanai, K.; Tagawa, M. The role of positron emission tomography in neuropharmacology in the living human brain and drug development. Nippon Rinsho. 58:2149-2157;2000.
5. Phelps M.E., Mazziotta J.C., Baxter L., Gerner R. Positron emission tomographic study of affective disorders: problems and strategies. Ann. Neurol. 15:S149-S156; 1984.
6. Phelps, M.E. PET: a biological imaging technique. Neurochem. Res. 16:929-940; 1991.
7. Vaalburg, W.; Hendrikse, N.H.; de Vries E.F. Drug development, radiolabelled drugs and PET. Ann. Med. 31:432-437; 1999.
8. Aboagye, E.O.; Price, P.M.; Jones T. In vivo pharmacokinetics and pharmacodynamics in drug development using positron-emission tomography. Drug Discov. Today 6:293-302; 2001.
9. Phelps, M.E.; Schelbert, H.R.; Mazziotta J.C. Positron computed tomography for studies of myocardial and cerebral function. Ann. Intern. Med. 98:339-359; 1983.
10. Jones, T. Present and future capabilities of molecular imaging techniques to understand brain function. J. Psychopharmacol. 13:324-329; 1999.
11. Haberkorn, U.; Altmann, A.; Eisenhut, M. Functional genomics and proteomics - the role of nuclear medicine. Eur. J. Nucl. Med. 29:115-132; 2002.
12. Dimitrakopoulou-Strauss, A.; Strauss, L.G.; Gutzler, F.; et al. Pharmacokinetic imaging of 11C ethanol with PET in eight patients with hepatocellular carcinomas who were scheduled for treatment with percutaneous ethanol injection. Radiology 211:681-686; 1999.
13. Fischman, A.J.; Bonab, A.A.; Rubin, R.H. Regional pharmacokinetics of orally administered PET tracers. Curr. Pharm. Des. 6(16):1625-1629; 2000.
14. Foster, K.A.; Roberts, M.S. Experimental methods for studying drug uptake in the head and brain. Curr. Drug Metab. 1:333-356; 2000.
15. Zunkeler, B.; Carson, R.E.; Olson J.; et al. Quantification and pharmacokinetics of blood-brain barrier disruption in humans. J. Neurosurg. 85:1056-1065; 1996.
16. Dolovich, M.B. Measuring total and regional lung deposition using inhaled radiotracers. J. Aerosol Med. 14:S35-S44; 2001.
17. Lee, Z.; Berridge, M.S.; Finlay, W.H.; Heald, D.L. Mapping PET-measured triamcinolone acetonide (TAA) aerosol distribution into deposition by airway generation. Int. J. Pharm. 199:7-16; 2000.
18. Yanai, M.; Hatazawa, J.; Ojima, F.; Sasaki, H.; Itoh, M.; Ido, T. Deposition and clearance of inhaled 18FDG powder in patients with chronic obstructive pulmonary disease. Eur. Respir. J. 11:1342-1348; 1998.
19. Suhara, T.; Sudo, Y.; Yoshida, K.; et al. Lung as reservoir for antidepressants in pharmacokinetic drug interactions. Lancet 351:332-335; 1998.
20. Waarde, A.V. Measuring receptor occupancy with PET. Curr. Pharm. Des. 6:1593-1610; 2000.
21. Rousseau, A.; Marquet, P.; Debord, J.; Sabot, C.; Lachatre,G. Adaptive control methods for the dose individualization of anticancer agents. Clin. Pharmacokinet. 38:315-353; 2000.
22. Saleem, A.; Harte, R.J.; Matthews, J.C.; et al. Pharmacokinetic evaluation of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in patients by positron emission tomography. J. Clin. Oncol. 19:1421-1429; 2001.
23. Fischman, A.J.; Babich, J.W.; Bonab, A.A.; et al. Pharmacokinetics of [18F]trovafloxacin in healthy human subjects studied with positron emission tomography. Antimicrob. Agents Chemother. 42:2048-2054; 1998.
24. Fischman, A.J.; Livni, E.; Babich, J.W.; et al. Pharmacokinetics of [18F]fleroxacin in patients with acute exacerbations of chronic bronchitis and complicated urinary tract infection studied by positron emission tomography. Antimicrob. Agents Chemother. 40:659-664; 1996.
25. Meikle, S.R.; Matthews, J.C.; Brock, C.S.; et al. Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: a feasibility study. Cancer Chemother. Pharmacol. 42:183-193; 1998.
26. Lee, M.C.; Wagner, H.N. Jr; Tanada, S.; Frost, J.J.; Bice,A.N.; Dannals, R.F. Duration of occupancy of opiate receptors by naltrexone. J. Nucl. Med. 29:1207-1211; 1988.
27. Christian, B.T.; Livni, E.; Babich, J.W.; et al. Evaluation of cerebral pharmacokinetics of the novel antidepressant drug, BMS-181101, by positron emission tomography. J. Pharmacol. Exp. Ther. 279:325-331; 1996.
28. Camsonne, R.; Barre, L.; Petit-Taboue, M.C.; et al. Positron emission tomographic studies of [11C]MDL 72222, a potential 5-HT3 receptor radioligand: distribution, kinetics and binding in the brain of the baboon. Neuropharmacology 32:65-71; 1993.
29. Offord, S.J.; Wong, D.F.; Nyberg, S. The role of positron emission tomography in the drug development of M100907, a putative antipsychotic with a novel mechanism of action. J. Clin. Pharmacol.331 39 (suppl):17S-24S; 1999.
30. Kissel, J.; Brix, G.; Bellemann, M.E., et al. Pharmacokinetic analysis of 5-[18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma. Cancer Res. 57:3415-3423; 1997.
31. Nilsson, D.; Lennernas, H.; Fasth, K.J.; et al. Absorption of L-DOPA from the proximal small intestine studied in the rhesus monkey by positron emission tomography. Eur. J. Pharm. Sci. 7:185-189; 1999.
32. Haradahira, T.; Zhang, M.; Maeda, J.; et al. A strategy for increasing the brain uptake of a radioligand in animals: use of a drug that inhibits plasma protein binding. Nucl. Med. Biol. 27:357-360; 2000.
33. Osman, S.; Luthra, S.K.; Brady, F.; et al. Studies on the metabolism of the novel antitumor agent [N-methyl-11C] N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in rats and humans prior to phase I clinical trials. Cancer Res. 57:2172-2180; 1997.
34. Nyberg, S.; Dahl, M.L.; Halldin, C. A PET study of D2 and 5-HT2 receptor occupancy induced by risperidone in poor metabolizers of debrisoquin and risperidone. Psychopharmacology (Berl) 119:345-348; 1995.
35. Strauss L.G. Positron emission tomography: current role for diagnosis and therapy monitoring in oncology. Oncologist 2:381-388; 1997.
36. Hendrikse, N.H.; Franssen, E.J.; van der Graaf, W.T.; Vaalburg, W.; de Vries, E.G. Visualization of multidrug resistance in vivo. Eur. J. Nucl. Med. 26:283-293; 1999.
37. Bart, J.; Groen, H.J.; Hendrikse, N.H.; van der Graaf,W.T.; Vaalburg, W.; de Vries, E.G. The blood-brain barrier and oncology: new insights into function and modulation. Cancer Treat Rev. 26:449-462; 2000.
38. Hendrikse, N.H.; de Vries, E.G.; Eriks-Fluks, L.; et al. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. Cancer Res. 59:2411-2416; 1999.
39. Sharma, V.; Beatty, A.; Wey, S.P.; et al. Novel gallium(III) complexes transported by MDR1 P-glycoprotein: potential PET imaging agents for probing P-glycoprotein-mediated transport activity in vivo. Chem. Biol. 7:335-343; 2000.
40. Hendrikse, N.H. Monitoring interactions at ATP-dependent drug efflux pumps. Curr. Pharm. Des. 6:1653-1668; 2000.
41. Oku, N.; Tokudome, Y.; Tsukada, H.; Okada, S. Realtime analysis of liposomal trafficking in tumor-bearing mice by use of positron emission tomography. Biochim. Biophys. Acta. 1238:86-90; 1995.
42. Oku, N.; Tokudome, Y.; Tsukada, H.; Kosugi, T.; Namba, Y.; Okada, S. In vivo trafficking of long-circulating liposomes in tumor-bearing mice determined by positron emission tomography. Biopharm. Drug Dispos. 17:435-441; 1996.
43. Asai, T.; Shuto, S.; Matsuda, A.; et al. Targeting and anti-tumor efficacy of liposomal 5′-O-dipalmitoylphosphatidyl 2′- C-cyano-2′-deoxy-1-beta-D-arabino-pentofuranosylcytosine in mice lung bearing B16BL6 melanoma. Cancer Lett. 162:49-56; 2001.
44. Frost, J.J. Measurement of neurotransmitter receptors by positron emission tomography: focus on the opiate receptor. NIDA Res. Monogr. 74:15-24; 1986.
45. Farde, L. The advantage of using positron emission tomography in drug research. Trends Neurosci. 19:211-214; 1996.
46. Zamuner, S.; Gomeni, R.; Bye, A. Estimate the time varying brain receptor occupancy in PET imaging experiments using non-linear fixed and mixed effect modeling approach. Nucl. Med. Biol. 29:115-123; 2002.
47. Kegeles, L.S.; Martinez, D.; Kochan, L.D.; et al. NMDA antagonist effects on striatal dopamine release: positron emission tomography studies in humans. Synapse 43:19-29; 2002.
48. Farde, L.; Andree, B.; Ginovart, N.; Halldin, C.; Thorberg,S. PET-Determination of robalzotan (NAD-299) induced 5-HT(1A) receptor occupancy in the monkey brain. Neuropsychopharmacology 22:422-429; 2000.
49. Nyberg, S.; Eriksson, B.; Oxenstierna, G.; Halldin, C.; Farde, L. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients. Am. J. Psychiatry 156:869-875; 1999.
50. Christian, B.T.; Babich, J.W.; Livni, E.; et al. Positron emission tomographic analysis of central dopamine D1 receptor binding in normal subjects treated with the atypical neuroleptic, SDZ MAR 327. Int. J. Mol. Med. 1:243-247; 1998.
51. Volkow, N.D.; Wang, G.J.; Fischman, M.W.; et al. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature 386:827-830; 1997.
52. Pauli, S.; Sedvall, G. Three-dimensional visualization and quantification of the benzodiazepine receptor population within a living human brain using PET and MRI. Eur. Arch. Psychiatry Clin. Neurosci. 247:61-70; 1997.
53. Roth, B.L.; Ernsberger, P.; Steinberg, S.A.; et al. The in vitro pharmacology of the beta-adrenergic receptor pet ligand (s)-fluorocarazolol reveals high affinity for cloned beta-adrenergic receptors and moderate affinity for the human 5-HT1A receptor. Psychopharmacology (Berl) 157:111-114; 2001.
54. Hume, S.P.; Ashworth, S.; Lammertsma, A.A.; et al. Evaluation in rat of RS-79948-197 as a potential PET ligand for central alpha 2-adrenoceptors. Eur. J. Pharmacol. 317:67-73; 1996.
55. Mathews, W.B.; Scheffel, U.; Finley, P.; et al. Biodistribution of [18F] SR144385 and [18F] SR147963: selective radioligands for positron emission tomographic studies of brain cannabinoid receptors. Nucl. Med. Biol. 27:757-762; 2000.
56. Haradahira, T.; Zhang, M.R.; Maeda, J.; et al. A prodrug of NMDA/glycine site antagonist, L-703,717, with improved BBB permeability: 4-acetoxy derivative and its positron-emitter labeled analog. Chem. Pharm. Bull. (Tokyo) 49:147-150; 2001.
57. Sudo, Y.; Suhara, T.; Suzuki, K.; et al. Muscarinic receptor occupancy by biperiden in living human brain. Life Sci. 64:PL99-PL104; 1999.
58. Mayberg, H.S.; Brannan, S.K.; Tekell, J.L.; et al. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol. Psychiatry 48:830-843; 2000.
59. Martinez, D.; Broft, A.; Laruelle, M. Pindolol augmentation of antidepressant treatment: recent contributions from brain imaging studies. Biol. Psychiatry 48:844-853; 2000.
60. Andree, B.; Thorberg, S.O.; Halldin, C.; Farde, L. Pindolol binding to 5-HT1A receptors in the human brain confirmed with positron emission tomography. Psychopharmacology (Berl) 144:303-305; 1999.
61. Trichard, C.; Paillere-Martinot, M.L.; Attar-Levy, D.; Recassens,C.; Monne,t F.; Martinot, J.L. Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients. Am. J. Psychiatry 155:505-508; 1998.
62. Volkow, N.D.; Wang, G.J.; Fowler, J.S.; et al. Methylphenidate and cocaine have a similar in vivo potency to block dopamine transporters in the human brain. Life Sci. 65:PL7-PL12; 1999.
63. Volkow, N.D.; Wang, G.J.; Fowler, J.S.; et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am. J. Psychiatry 155:1325-1331; 1998.
64. Wilcox, K.M.; Lindsey, K.P.; Votaw, J.R.; et al. Self-administration of cocaine and the cocaine analog RTI-113: relationship to dopamine transporter occupancy determined by PET neuroimaging in rhesus monkeys. Synapse 43:78-85; 2002.
65. Hartvig, P.; Torstenson, R.; Tedroff, J.; et al. Amphetamine effects on dopamine release and synthesis rate studied in the Rhesus monkey brain by positron emission tomography. J. Neural. Transm. 104:329-339; 1997.
66. Villemagne, V.L.; Rothman, R.B.; Yokoi, F.; et al. Doses of GBR12909 that suppress cocaine self-administration in non-human primates substantially occupy dopamine transporters as measured by [11C] WIN35,428 PET scans. Synapse 32:44-50; 1999.
67. Danielsen, E.H.; Smith, D.; Hermansen, F.; Gjedde, A.; Cumming, P. Acute neuroleptic stimulates DOPA decarboxylase in porcine brain in vivo. Synapse 41:172-175; 2001.
68. Hume, S.P.; Opacka-Juffry, J.; Myers, R.; et al. Effect of L-dopa and 6-hydroxydopamine lesioning on [11C] raclopride binding in rat striatum, quantified using PET. Synapse 21:45-53; 1995.
69. Piccini, P.; Weeks, R.A.; Brooks, D.J. Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias. Ann. Neurol. 42:720-726; 1997.
70. Ceravolo, R.; Piccini, P.; Bailey, D.L.; Jorga, K.M.; Bryson,H.; Brooks, D.J. 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. Synapse 43:201-207; 2002.
71. Farde, L.; Wiesel, F.A.; Halldin, C.; Sedvall, G. Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch. Gen. Psychiatry 45:71-76; 1988.
72. Nyberg, S.; Farde, L.; Halldin, C. A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology 16:1-7; 1997.
73. Kapur, S.; Zipursky, R.; Jones, C.; Shammi, C.S.; Remington,G.; Seeman, P. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch. Gen. Psychiatry 57:553-559; 2000.
74. Holcomb, H.H.; Cascella, N.G.; Thaker, G.K.; Medoff,D.R.; Dannals, R.F.; Tamminga, C.A. Functional sites of neuroleptic drug action in the human brain: PET/FDG studies with and without haloperidol. Am. J. Psychiatry 153:41-49; 1996.
75. Black, K.J.; Hershey, T.; Gado, M.H.; Perlmutter, J.S. Dopamine D(1) agonist activates temporal lobe structures in primates. J. Neurophysiol. 84:549-557; 2000.
76. Volkow, N.D.; Wang, G.; Fowler, J.S.; et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. J. Neurosci. 21:RC121; 2001.
77. Juhasz, C.; Muzik, O.; Chugani, D.C.; Shen, C.; Janisse, J.; Chugani, H.T. Prolonged vigabatrin treatment modifies developmental changes of GABA(A)-receptor binding in young children with epilepsy. Epilepsia 42:1320-1326; 2001.
78. Schmid, L.; Bottlaender, M.; Brouillet, E.; Fuseau, C.; Maziere,M. Vigabatrin modulates benzodiazepine receptor activity in vivo: a positron emission tomography study in baboon. J. Pharmacol. Exp. Ther. 276:977-983; 1996.
79. Chavoix, C.; Brouillet, E.; Kunimoto, M., et al. Relationships between benzodiazepine receptors, impairment of GABAergic transmission and convulsant activity of beta-CCM: a PET study in the baboon Papio papio. Epilepsy Res. 8:1-10; 1991.
80. Brouillet, E.; Chavoix, C.; Bottlaender, M.; et al. In vivo bidirectional modulatory effect of benzodiazepine receptor ligands on GABAergic transmission evaluated by positron emission tomography in non-human primates. Brain Res. 557:167-176; 1991.
81. Reinsel, R.A.; Veselis, R.A.; Dnistrian, A.M.; Feshchenko,V.A.; Beattie, B.J.; Duff, M.R. Midazolam decreases cerebral blood flow in the left prefrontal cortex in a dosedependent fashion. Int. J. Neuropsychopharmacol. 3:117-127; 2000.
82. Coull, J.T.; Frith, C.D.; Dolan, R.J. Dissociating neuromodulatory effects of diazepam on episodic memory encoding and executive function. Psychopharmacology (Berl) 145:213-222; 1999.
83. Mintzer, M.Z.; Griffiths, R.R.; Contoreggi, C.; Kimes, A.S.; London, E.D.; Ernst, M. Effects of Triazolam on Brain Activity During Episodic Memory Encoding: A PET Study. Neuropsychopharmacology 25:744-756; 2001.
84. Gyulai, F.E.; Mintun, M.A.; Firestone, L.L. Dose-dependent enhancement of in vivo GABA(A)-benzodiazepine receptor binding by isoflurane. Anesthesiology 95(3):585-593; 2001.
85. Bonhomme, V.; Fiset, P.; Meuret, P.; et al. Propofol anesthesia and cerebral blood flow changes elicited by vibrotactile stimulation: a positron emission tomography study. J. Neurophysiol. 85:1299-1308; 2001.
86. Fiset, P.; Paus, T.; Daloze, T.; et al. Brain mechanisms of propofol-induced loss of consciousness in humans: a positron emission tomographic study. J. Neurosci. 19:5506-5513; 1999.
87. Muhr, C.; Gudjonsson, O; Lilja, A.; et al. Meningioma treated with interferon-alpha, evaluated with [(11)C]-Lmethionine positron emission tomography. Clin. Cancer Res. 7:2269-2276; 2001.
88. Rischin, D.; Peters, L.; Hicks, R.; et al. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J. Clin. Oncol. 19:535-542; 2001.
89. Saleem, A.; Yap, J.; Osman, S.; et al. Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action. Lancet 355:2125-2131; 2000.
90. Robbins, R.J.; Hill, R.H.; Wang, W.; Macapinlac, H.H.; Larson, S.M. Inhibition of metabolic activity in papillary thyroid carcinoma by a somatostatin analogue. Thyroid 10:177-183; 2000.
91. Collins, J.M.; Klecker, R.W.; Katki, A.G. Suicide pro-drugs activated by thymidylate synthase: rationale for treatment and noninvasive imaging of tumors with deoxyuridine analogues. Clin. Cancer Res. 5:1976-1981; 1999.
92. Harte, R.J.; Matthews, J.C.; O'Reilly, S.M., et al. Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alpha. J. Clin. Oncol. 17:1580-1588; 1999.
93. Zhang, Z.J.; Wang, J.L.; Muhr, C.; Smits, A. Synergistic inhibitory effects of interferon-alpha and 5-fluorouracil in meningioma cells in vitro. Cancer Lett. 100:99-105; 1996.
94. Coull, J.T.; Buchel, C.; Friston, K.J.; Frith, C.D. Noradrenergically mediated plasticity in a human attentional neuronal network. Neuroimage 10:705-715; 1999.
95. Nordberg, A.; Amberla, K.; Shigeta, M.; et al. Long-term tacrine treatment in three mild Alzheimer patients: effects on nicotinic receptors, cerebral blood flow, glucose metabolism, EEG, and cognitive abilities. Alzheimer Dis. Assoc. Disord. 12:228-237; 1998.
96. Mody, F.V.; Singh, B.N.; Mohiuddin, I.H.; et al. Trimetazidine-induced enhancement of myocardial glucose utilization in normal and ischemic myocardial tissue: an evaluation by positron emission tomography. Am. J. Cardiol. 82:42K-49K; 1998.
97. Inoue, T.; Kim, E.E.; Wallace, S.; et al. Preliminary study of cardiac accumulation of F-18 fluorotamoxifen in patients with breast cancer. Clin. Imaging 21(5):332-336; 1997.
98. Qing, F.; McCarthy, T.J.; Markham, J.; Schuster, D.P. Pulmonary angiotensin-converting enzyme (ACE) binding and inhibition in humans. A positron emission tomography study. Am. J. Respir. Crit. Care Med. 161:2019-2025; 2000.
99. Saiki, I.; Koike, C.; Obata, A.; et al. Functional role of sialyl Lewis X and fibronectin-derived RGDS peptide analogue on tumor-cell arrest in lungs followed by extravasation. Int. J. Cancer 65:833-839; 1996.
100. Benkelfat, C.; Bradwejn, J.; Meyer, E.; et al. Functional neuroanatomy of CCK4-induced anxiety in normal healthy volunteers. Am. J. Psychiatry 152:1180-1184; 1995.
101. Heinonen, E.H.; Anttila, M.I.; Lammintausta, R.A. Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites. Clin. Pharmacol. Ther. 56:742-749; 1994.
102. Fowler, J.S.; Wang, G.J.; Volkow, N.D., et al. Evidence that gingko biloba extract does not inhibit MAO A and B in living human brain. Life Sci. 66:PL141-146; 2000.
103. Gjedde, A. Receptor mapping in living human beings by means of positron emission tomography. Ugeskr. Laeger. 163:5199-5205; 2001.
104. Laakso, A..; Hietala, J. PET studies of brain monoamine transporters. Curr. Pharm. Des. 6:1611-1623; 2000.
105. 11C][beta]-CIT-FE binding to the dopamine transporter in the monkey and human brain. Int. J. Neuropsychopharmacol. 3:203-214; 2000.
106. Pike, V.W.; Halldin, C.; Wikstrom, H.; et al. Radioligands for the study of brain 5-HT(1A) receptors in vivo-development of some new analogues of way. Nucl. Med. Biol. 27:449-455; 2000.
107. Takahashi, T.; Nishimura, S.; Ido, T.; Ishiwata, K.; Iwata,R. Biological evaluation of 5-methyl-branched-chain omega-[18F]fluorofatty acid: a potential myocardial imaging tracer for positron emission tomography. Nucl. Med. Biol. 23:303-308; 1996.
108. Pelegrin, A.; Xavier, F.; Barbet, J.; et al. Immunotargeting of tumors: state of the art and prospects in 2000. Bull. Cancer 87:777-791; 2000.
109. Passchier, J.; van Waarde, A. Visualization of serotonin-1A (5-HT1A) receptors in the central nervous system. Eur. J. Nucl. Med. 28:113-129; 2001.
110. Mayberg, H.S.; Brannan, S.K.; Mahurin, R.K.; et al. Cingulate function in depression: a potential predictor of treatment response. Neuroreport. 8:1057-1061; 1997.
111. el Mansari, M.; Bouchard, C.; Blier, P. Alteration of serotonin release in the guinea pig orbito-frontal cortex by selective serotonin reuptake inhibitors. Relevance to treatment of obsessive-compulsive disorder. Neuropsychopharmacology 13:117-127; 1995.
112. Swedo, S.E.; Pietrini, P.; Leonard, H.L.; et al. Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Revisualization during pharmacotherapy. Arch. Gen. Psychiatry 49:690-694; 1992.
113. Baxter, L.R. Jr; Schwartz, J.M.; Bergman, K.S.; et al. Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Arch. Gen. Psychiatry 49:681-689; 1992.
114. Fowler, J.S.; Volkow, N.D. PET imaging studies in drug abuse. J. Toxicol. Clin. Toxicol. 36:163-174; 1998.
115. Sell, L.A.; Morris, J.S.; Bearn, J.; Frackowiak, R.S.; Friston,K.J.; Dolan, R.J. Neural responses associated with cue evoked emotional states and heroin in opiate addicts. Drug Alcohol Depend. 60:207-216; 2000.
116. Volkow, N.D.; Chang, L.; Wang, G.J.; et al. Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. Am. J. Psychiatry 158:2015-2021; 2001.
117. Volkow, N.D.; Wang, G.J.; Fowler, J.S.; et al. Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D(2) receptors. J. Pharmacol. Exp. Ther. 291:409-415; 1999.
118. Wang, G.J.; Volkow, N.D.; Fowler, J.S.; et al. Regional brain metabolic activation during craving elicited by recall of previous drug experiences. Life Sci. 64:775-784; 1999.
119. Weinstein, A.; Feldtkeller, B.; Malizia, A.; Wilson, S.; Bailey, J.; Nutt, D.J. Integrating the cognitive and physiological aspects of craving. J. Psychopharmacol. 12:31-38; 1998.
120. London, E.D.; Bonson, K.R.; Ernst, M.; Grant, S. Brain imaging studies of cocaine abuse: implications for medication development. Crit. Rev. Neurobiol. 13:227-242; 1999.
121. Wu, J.C.; Bell, K.; Najafi, A.; et al. Decreasing striatal 6-FDOPA uptake with increasing duration of cocaine withdrawal. Neuropsychopharmacology 17:402-409; 1997.
122. Volkow, N.D.; Fowler, J.S.; Wolf, A.P.; et al. Changes in brain glucose metabolism in cocaine dependence and withdrawal. Am. J. Psychiatry 148:621-626; 1991.
123. Cohen, R.M.; Nordahl, T.E.; Semple, W.E.; Andreason, P.; Litman, R.E.; Pickar, D. The brain metabolic patterns of clozapine- and fluphenazine-treated patients with schizophrenia during a continuous performance task. Arch. Gen. Psychiatry 54:481-486; 1997.
124. Suhara, T.; Okubo, Y.; Yasuno, F.; et al. Decreased dopamine D2 receptor binding in the anterior cingulate cortex in schizophrenia. Arch. Gen. Psychiatry 59:25-30; 2002.
125. Davis, K.L.; Kahn, R.S.; Ko, G.; Davidson, M. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry 148:1474-1486; 1991.
126. Sabri, O.; Erkwoh, R.; Schreckenberger, M.; Owega, A.; Sass, H.; Buell, U. Correlation of positive symptoms exclusively to hyperperfusion or hypoperfusion of cerebral cortex in never-treated schizophrenics. Lancet 349:1735-1739; 1997.
127. Potkin, S.G.; Alva, G.; Fleming, K.; et al. A PET study of the pathophysiology of negative symptoms in schizophrenia. Am. J. Psychiatry 159:227-237; 2002.
128. Okubo, Y.; Suhara, T.; Suzuki, K.; et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 385:634-636; 1997.
129. Szymanski, S.; Gur, R.C.; Gallacher, F.; Mozley, L.H.; Gur, R.E. Vulnerability to tardive dyskinesia development in schizophrenia: an FDG-PET study of cerebral metabolism. Neuropsychopharmacology 15:567-575; 1996.
130. Tamminga, C. Glutamatergic aspects of schizophrenia. Br. J. Psychiatry 37(suppl):12-15; 1999.
131. Lang, W.; Hollinger, P.; Eghker, A.; Lindinger, G. Functional localization of motor processes in the primary and supplementary motor areas. J. Clin. Neurophysiol. 11:397-419; 1994.
132. Ouchi, Y.; Kanno, T.; Okada, H.; et al. Presynaptic and postsynaptic dopaminergic binding densities in the nigrostriatal and mesocortical systems in early Parkinson's disease: a double-tracer positron emission tomography study. Ann. Neurol. 46:723-731; 1999.
133. Lee, C.S.; Samii, A.; Sossi, V.; et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann. Neurol. 47:493-503; 2000.
134. Frey, K.A.; Koeppe, R.A.; Kilbourn, M.R.; Van der Borght, T.M.; Albin, R.L.; Gilman, S.; Kuhl, D.E. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Ann. Neurol. 40:873-884; 1996.
135. de la Fuente-Fernandez, R.; Ruth, T.J.; Sossi, V.; Schulzer, M.; Calne, D.B.; Stoessl, A.J. Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease. Science 293:1164-1166; 2001.
136. Brooks, D.J.; Piccini, P.; Turjanski, N.; Samuel, M. Neuroimaging of dyskinesia. Ann. Neurol. 47:S154-S159; 2000.
137. Deuschl, G.; Raethjen, J.; Lindemann, M.; Krack, P. The pathophysiology of tremor. Muscle Nerve 24:716-735; 2001.
138. Savic, I.; Thorell, J.O. Localized cerebellar reductions in benzodiazepine receptor density in human partial epilepsy. Arch. Neurol. 53:656-662; 1996.
139. Friston, K.J.; Grasby, P.M.; Bench, C.J.; et al. Measuring the neuromodulatory effects of drugs in man with positron emission tomography. Neurosci. Lett. 141:106-110; 1992.
140. Coull, J.T.; Frith, C.D.; Frackowiak, R.S.; Grasby, P.M. A fronto-parietal network for rapid visual information processing: a PET study of sustained attention and working memory. Neuropsychologia 34:1085-1095; 1996.
141. Sihver, W.; Langstrom, B.; Nordberg, A. Ligands for in vivo imaging of nicotinic receptor subtypes in Alzheimer brain. Acta. Neurol. Scand. Suppl. 176:27-33; 2000.
142. Korf, J. Imaging of receptors in clinical neurosciences. Acta. Neurol. Belg. 97:200-205; 1997.
143. Coull, J.T.; Frith, C.D.; Dolan, R.J.; Frackowiak, R.S.; Grasby, P.M. The neural correlates of the noradrenergic modulation of human attention, arousal and learning. Eur. J. Neurosci. 9:589-598; 1997.
144. Bryant, C.A.; Jackson, S.H. Functional imaging of the brain in the evaluation of drug response and its application to the study of aging. Drugs Aging 13:211-222; 1998.
145. Syrota, A. Cardiac receptors studied by positron emission tomography. Acta. Radiol. Suppl. 374:85-91; 1990.
146. Goldstein, D.S.; Eisenhofer, G.; Dunn, B.B.; et al. Positron emission tomographic imaging of cardiac sympathetic innervation using 6-[18F]fluorodopamine: initial findings in humans. J. Am. Coll. Cardiol. 22:1961-1971; 1993.
147. Pike, V.W.; Law, M.P.; Osman, S.; et al. Selection, design and evaluation of new radioligands for PET studies of cardiac adrenoceptors. Pharm. Acta. Helv. 74:191-200; 2000.
148. Klecker, R.W. Jr; Collins, J.M. Thymidine phosphorylase as a target for imaging and therapy with thymine analogs. Cancer Chemother. Pharmacol. 48:407-412; 2001.
149. Laurent, B.; Peyron, R.; Garcia Larrea, L.; Mauguiere, F. Positron emission tomography to study central pain integration. Rev. Neurol. (Paris) 156:341-351; 2000.
150. Sachs, H.; Wolf, A.; Russell, J.A.; Christman, D.R. Effect of reserpine on regional cerebral glucose metabolism in control and migraine subjects. Arch. Neurol. 43:1117-1123; 1986.
151. Baron, J.C. Dementias and memory impairment of degenerative origin. Rev. Neurol. (Paris)154 (suppl):S122-S130; 1998.
152. Elkashef, A.M.; Doudet, D.; Bryant, T.; Cohen, R.M.; Li, S.H.; Wyatt, R.J. 6-(18)F-DOPA PET study in patients with schizophrenia. Positron emission tomography. Psychiatry Res. 100:1-11; 2000.
153. Lahti, A.C.; Holcomb, H.H.; Medoff, D.R.; Weiler, M.A.; Tamminga, C.A.; Carpenter, W.T. Jr. Abnormal patterns of regional cerebral blood flow in schizophrenia with primary negative symptoms during an effortful auditory recognition task. Am. J. Psychiatry 158:1797-1808; 2001.
154. Schreiner, R.; Mirisch, S.; Vesely, Z.; Wiegand, M.H. Sleep and sleep-wake cycle in an 81-year-old patient with de novo ultra-rapid cycling bipolar disorder. Eur. Arch. Psychiatry Clin. Neurosci. 251:29-31; 2001.
155. Lucignani, G.; Tassi, L.; Fazio, F.; et al. Double-blind stereo-EEG and FDG PET study in severe partial epilepsies: are the electric and metabolic findings related? Eur. J. Nucl. Med. 23:1498-1507; 1996.
156. Galardi, G.; Perani, D.; Grassi, F.; et al. Basal ganglia and thalamo-cortical hypermetabolism in patients with spasmodic torticollis. Acta. Neurol. Scand. 94:172-176; 1996.
157. Mann, J.J.; Malone, K.M.; Diehl, D.J.; Perel, J.; Nichols, T.E.; Mintun, M.A. Positron emission tomographic imaging of serotonin activation effects on prefrontal cortex in healthy volunteers. J. Cereb. Blood Flow Metab. 16:418-426; 1996.
158. Baxter, L.R. Jr; Phelps, M.E.; Mazziotta, J.C.; Guze, B.H.; Schwartz, J.M.; Selin, C.E. Local cerebral glucose metabolic rates in obsessive-compulsive disorder. A comparison with rates in unipolar depression and in normal controls. Arch. Gen. Psychiatry 44:211-218; 1987.
159. Moehler, M.; Dimitrakopoulou-Strauss, A.; Gutzler, F.; Raeth, U.; Strauss, L.G.; Stremmel, W. 18F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil. Cancer 83:245-253; 1998.
160. Paule, M.G.; Bushnell, P.J.; Maurissen, J.P.; et al. Symposium overview: the use of delayed matching-to-sample procedures in studies of short-term memory in animals and humans. Neurotoxicol. Teratol. 20:493-502; 1998.
161. Fischer, H.; Andersson, J.L.; Furmark, T.; Fredrikson, M. Brain correlates of an unexpected panic attack: a human positron emission tomographic study. Neurosci. Lett. 251:137-140; 1998.
162. Doudet, D.; Hommer, D.; Higley, J.D.; et al. Cerebral glucose metabolism, CSF 5-HIAA levels, and aggressive behavior in rhesus monkeys. Am. J. Psychiatry 152:1782-1787; 1995.
163. Ketter, T.A.; Kimbrell, T.A.; George, M.S.; et al. Effects of mood and subtype on cerebral glucose metabolism in treatment-resistant bipolar disorder. Biol. Psychiatry 49:97-109; 2001.
164. Kishimoto, H.; Yamada, K.; Iseki, E.; Kosaka, K.; Okoshi, T. Brain imaging of affective disorders and schizophrenia. Psychiatry Clin. Neurosci. 52 (suppl):S212-S214; 1998.
165. Vollenweider, F.X.; Maguire, R.P.; Leenders, K.L.; Mathys, K.; Angst, J. Effects of high amphetamine dose on mood and cerebral glucose metabolism in normal volunteers using positron emission tomography (PET). Psychiatry Res. 83:149-162; 1998.
166. Hietala, J.; Syvalahti, E.; Vilkman, H.; et al. Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia. Schizophr. Res. 35:41-50; 1999.
167. . Volkow, N.D.; Fowler, J.S.; Wang, G.J. Imaging studies on the role of dopamine in cocaine reinforcement and addiction in humans. J. Psychopharmacol. 13:337-345; 1999.
168. Leenders, K.L.; Oertel, W.H. Parkinson's disease: clinical signs and symptoms, neural mechanisms, positron emission tomography, and therapeutic interventions. Neural. Plast. 8:99-110; 2001.
169. Antonini, A.; Moresco, R.M.; Gobbo, C.; et al. The status of dopamine nerve terminals in Parkinson's disease and essential tremor: a PET study with the tracer [11-C]FECIT. Neurol. Sci. 22:47-48; 2001.
170. Winogrodzka, A.; Wagenaar, R.C.; Bergmans, P.; et al. Rigidity decreases resting tremor intensity in Parkinson's disease: A [(123)I]beta-CIT SPECT study in early, nonmedicated patients. Mov. Disord. 16:1033-1040; 2001.
171. Torstenson, R.; Hartvig, P.; Langstrom, B.; Westerberg, G.; Tedroff, J. Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease. Ann. Neurol. 41:334-340; 1997.
172. Brooks, D.J. Detection of preclinical Parkinson's disease with PET. Geriatrics 46 (suppl):25-30; 1991.
173. Wiesel, F.A.; Wik, G.; Sjogren, I.; Blomqvist, G.; Greitz, T.; Stone-Elander, S. Regional brain glucose metabolism in drug free schizophrenic patients and clinical correlates. Acta. Psychiatr. Scand. 76:628-641; 1987.
174. Young, A.B.; Penney, J.B.; Starosta-Rubinstein, S.; et al. PET scan investigations of Huntington's disease: cerebral metabolic correlates of neurological features and functional decline. Ann. Neurol. 20:296-303; 1986.
175. Siebelink, H.M.; Blanksma, P.K.; Crijns, H.J.; et al. No difference in cardiac event-free survival between positron emission tomography-guided and single-photon emission computed tomography-guided patient management: a prospective, randomized comparison of patients with suspicion of jeopardized myocardium. J. Am. Coll. Cardiol. 37:81-88; 2001.
176. Baller, D.; Gleichmann, U.; Notohamiprodjo, G.; et al. Improved coronary vasodilator capacity by drug lipid lowering therapy in patients in the early stage of coronary atherosclerosis with reduced coronary reserves and moderate LDL hypercholesteremia. Z. Kardiol. 87 (suppl):136-144; 1998.
177. Gould, K.L. New concepts and paradigms in cardiovascular medicine: the noninvasive management of coronary artery disease. Am. J. Med. 104:2S-17S; 1998.
178. Glasspool, R.M.; Evans, T.R. Clinical imaging of cancer metastasis. Eur. J. Cancer 36(13 Spec No):1661-1670; 2000.
179. Bombardieri, E.; Crippa, F.; Maffioli, L.; et al. Nuclear medicine approaches for detection of axillary lymph node metastases. Q. J. Nucl. Med. 42:54-65; 1998.
180. Gimenez Roldan, S.; Mateo, D.; Martinez Gines, M.; Iniesta, I. The problem of accurate diagnosis of Parkinson disease. Neurologia. 14 (suppl):3-16; 1999.
181. Hristova, A.H.; Koller, W.C. Early Parkinson's disease: what is the best approach to treatment. Drugs Aging 17:165-181; 2000.
182. Larisch, R.; Klimke, A. Clinical impact of cerebral dopamine-D2 receptor scintigraphy. Nuklearmedizin. 37:245-250; 1998.
183. Takahashi, N.; Fujibayashi, Y.; Yonekura, Y.; et al. Evaluation of 62Cu labeled diacetyl-bis(N4-methylthiosemicarbazone) as a hypoxic tissue tracer in patients with lung cancer. Ann. Nucl. Med. 14:323-328; 2000.
184. Blend, M.J.; Abdel-Nabi, H. New methods for the staging of colorectal cancer using noninvasive techniques. Semin. Surg. Oncol. 12:253-263; 1996.
185. Levchenko, A.; Mehta, B.M.; Lee, J.B.; et al. Evaluation of 11C-colchicine for PET imaging of multiple drug resistance. J. Nucl. Med. 41:493-501; 2000.
186. Connors, T. Anticancer drug development: the way forward. Oncologist 1:180-181; 1996.
187. Koh, W.J.; Rasey, J.S.; Evans, M.L.; et al. Imaging of hypoxia in human tumors with [F-18]fluoromisonidazole. Int. J. Radiat. Oncol. Biol. Phys. 22:199-212; 1992.
188. Francavilla, T.L.; Miletich, R.S.; DeMichele, D.; et al. Positron emission tomography of pituitary macroadenomas: hormone production and effects of therapies. Neurosurgery 28:826-833; 1991.
189. Weber, W.A.; Ott, K.; Becker, K.; et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J. Clin. Oncol. 19:3058-3065; 2001.
190. Bartlett, E.J.; Brodie, J.D.; Simkowitz, P.; et al. Effect of a haloperidol challenge on regional brain metabolism in neuroleptic-responsive and nonresponsive schizophrenic patients. Am. J. Psychiatry 155:337-343; 1998.
191. Schlosser, R. Detection of neurotransmitter interactions with PET and SPECT by pharmacological challenge paradigms. Nervenarzt. 71:9-18; 2000.
192. Cohen, R.M.; Nordahl, T.E.; Semple, W.E.; Andreason, P.; Pickar, D. Abnormalities in the distributed network of sustained attention predict neuroleptic treatment response in schizophrenia Neuropsychopharmacology 19:36-47; 1998.
193. Buchsbaum, M.S.; Potkin, S.G.; Siegel, B.V. Jr; et al. Striatal metabolic rate and clinical response to neuroleptics in schizophrenia. Arch. Gen. Psychiatry 49:966-974; 1992.
194. Brody, A.L.; Saxena, S.; Silverman, D.H.; et al. Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine. Psychiatry Res. 91:127-139; 1999.
195. Tauscher, J.; Kapur, S. Choosing the right dose of antipsychotics in schizophrenia: lessons from neuroimaging studies. CNS Drugs 15:671-678; 2001.
196. Kapur, S.; Roy, P.; Daskalakis, J.; Remington, G.; Zipursky, R. Increased dopamine d(2) receptor occupancy and elevated prolactin level associated with addition of haloperidol to clozapine. Am. J. Psychiatry 158:311-314; 2001.
197. Silvestri, S.; Seeman, M.V.; Negrete, J.C.; et al. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: a clinical PET study. Psychopharmacology (Berl) 152:174-180; 2000.
198. Wadenberg, M.L.; Kapur, S.; Soliman, A.; Jones, C.; Vaccarino, F. Dopamine D2 receptor occupancy predicts catalepsy and the suppression of conditioned avoidance response behavior in rats. Psychopharmacology (Berl) 150:422-429; 2000.
199. Pinkofsky, H.B.; Dwyer, D.S.; Bradley, R.J. The inhibition of GLUT1 glucose transport and cytochalasin B binding activity by tricyclic antidepressants. Life Sci. 66:271-278; 2000.
200. Lewis, P.J.; Barrington, S.F.; Marsden, P.K.; Maisey, M.N.; Lewis, L.D. A study of the effects of sumatriptan on myocardial perfusion in healthy female migraineurs using 13NH3 positron emission tomography. Neurology 48:1542-1550; 1997.
201. Bergstrom, M.; Westerberg, G.; Nemeth, G.; et al. MAO-A inhibition in brain after dosing with esuprone, moclobemide and placebo in healthy volunteers: in vivo studies with positron emission tomography. Eur. J. Clin. Pharmacol. 52:121-128; 1997.
202. Gaillard, W.D.; Zeffiro, T.; Fazilat, S.; DeCarli, C.; Theodore, W.H. Effect of valproate on cerebral metabolism and blood flow: an 18F-2-deoxyglucose and 15O water positron emission tomography study. Epilepsia 37:515-521; 1996.
203. Leiderman, D.B.; Balish, M.; Bromfield, E.B.; Theodore, W.H. Effect of valproate on human cerebral glucose metabolism. Epilepsia 32:417-422; 1991.
204. Matochik, J.A.; Nordahl, T.E.; Gross, M.; et al. Effects of acute stimulant medication on cerebral metabolism in adults with hyperactivity. Neuropsychopharmacology 8:377-386; 1993.
205. Martinez, D.; Broft, A.; Laruelle, M. Imaging neurochemical endophenotypes: promises and pitfalls. Pharmacogenomics 2:223-237; 2001.
206. Paans, A.M.; Vaalburg, W. Positron emission tomography in drug development and drug evaluation. Curr. Pharm. Des. 6:1583-1591; 2000.
207. Ferrie, C.D.; Bird, S.; Tilling, K.; Maisey, M.N.; Chapman, A.G.; Robinson, R.O. Plasma amino acids in childhood epileptic encephalopathies. Epilepsy Res. 34:221-229; 1999.
208. Noble, E.P.; Gottschalk, L.A.; Fallon, J.H.; Ritchie, T.L.; Wu, J.C. D2 dopamine receptor polymorphism and brain regional glucose metabolism. Am. J. Med. Genet. 74:162-166; 1997.
209. Kishore, A.; Nygaard, T.G.; de la Fuente-Fernandez, R.; et al. Striatal D2 receptors in symptomatic and asymptomatic carriers of dopa-responsive dystonia measured with [11C]-raclopride and positron-emission tomography. Neurology 50:1028-1032; 1998.
210. Phelps, M.E. Inaugural article: positron emission tomography provides molecular imaging of biological processes. Proc. Natl. Acad. Sci. U S A 97:9226-9233; 2000.
211. Jacobs, A.; Dubrovin, M.; Hewett, J.; et al. Functional coexpression of HSV-1 thymidine kinase and green fluorescent protein: implications for noninvasive imaging of transgene expression. Neoplasia 1:154-161; 1999.
212. Blasberg, R.G.; Tjuvajev, J.G. Herpes simplex virus thymidine kinase as a marker/reporter gene for PET imaging of gene therapy. Q. J. Nucl. Med. 43:163-169; 1999.
213. Gambhir, S.S.; Bauer, E.; Black, M.E.; et al. A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography. Proc. Natl. Acad. Sci. U S A 97:2785-2790; 2000.
214. Bankiewicz, K.S.; Eberling, J.L.; Kohutnicka, M.; et al. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using prodrug approach. Exp. Neurol. 164:2-14; 2000.
215. Lindvall, O.; Hagell, P. Cell therapy and transplantation in Parkinson's disease. Clin. Chem. Lab. Med. 39:356-361; 2001.
216. Lindvall, O. Neural transplantation in Parkinson's disease. Novartis Found. Symp. 231:110-128, 145-147; 2000.
217. Piccini, P.; Brooks, D.J.; Bjorklund, A.; et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat. Neurosci. 2:1137-1140; 1999.
218. Subramanian, T.; Emerich, D.F.; Bakay, R.A.; et al. Polymer-encapsulated PC-12 cells demonstrate high-affinity uptake of dopamine in vitro and 18F-Dopa uptake and metabolism after intracerebral implantation in nonhuman primates. Cell Transplant. 6:469-477; 1997.
219. Moresco, R.M.; Colombo, C.; Fazio, F.; et al. Effects of fluvoxamine treatment on the in vivo binding of [F-18] FESP in drug naive depressed patients: a PET study. Neuroimage 12:452-465; 2000.
220. Meyer, J.H.; Kapur, S.; Eisfeld, B.; et al. The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study. Am. J. Psychiatry 158:78-85; 2001.
221. Buchert, R.; Obrocki, J.; Thomasius, R.; et al. Long-term effects of 'ecstasy' abuse on the human brain studied by FDG PET. Nucl. Med. Commun. 22:889-897; 2001.
222. List, S.J.; Cleghorn, J.M. Implications of positron emission tomography research for the investigation of the actions of antipsychotic drugs. Br. J. Psychiatry 22(suppl):25-30; 1993.
223. Melega, W.P.; Raleigh, M.J.; Stout, D.B.; Lacan, G.; Huang, S.C.; Phelps, M.E. Recovery of striatal dopamine function after acute amphetamine- and methamphetamine-induced neurotoxicity in the vervet monkey. Brain Res. 766:113-120; 1997.
224. Antonini, A.; Schwarz, J.; Oertel, W.H.; Pogarell, O.; Leenders, K.L. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride. Mov. Disord. 12:33-38; 1997.
225. Nordberg, A. Clinical studies in Alzheimer patients with positron emission tomography. Behav. Brain Res. 57:215-224; 1993.